USP <1207> Package Integrity Evaluation—Sterile Products

USP General Chapter <1207> provides a modern framework for ensuring the container-closure integrity (CCI) of sterile products. <1207> is a suite of informational chapters (<1207.1, <1207.2, <1207.3>). Its core philosophy is a major shift in industry best practice, advocating for the use of quantitative, deterministic methods (e.g., vacuum decay, HVLD) over older, qualitative probabilistic tests (e.g., dye ingress). The goal is to provide robust, scientific assurance that a product remains sterile throughout its lifecycle.

<1207> positions CCI testing as a critical component of the overall sterility assurance system, alongside validated aseptic processing and sterilization strategies.

Applicability: Sterile drug products, biologics, and advanced therapies that rely on sealed container–closure systems.

Lifecycle Application: Guidance applies from development and package design through validation, routine QC release, stability studies, and post-approval changes.

Deterministic vs. Probabilistic Methods
Deterministic (Preferred): Quantitative, non-destructive physical methods suitable for routine QC and 100% testing.

Examples: Helium Leak Detection, High Voltage Leak Detection (HVLD), Vacuum/Pressure Decay, Headspace Gas Analysis.

Probabilistic (Discouraged for QC): Qualitative tests with subjective results, now used primarily for package development, not routine release.

Examples: Dye Ingress, Microbial Challenge.

Key Concepts in Modern CCIT
Maximum Allowable Leakage Limit (MALL): A scientifically justified leak size threshold used to validate a deterministic method’s sensitivity to detect defects that could risk sterility.

Lifecycle Perspective: CCI evaluation is not a one-time test. Validated deterministic CCIT supports:

• Package design and selection
• Process validation
• QC release and in-process control
• Long-term stability programs
• Comparability protocols and post-approval changes